Back to search results

Study of Valemetostat, Rituximab, and Lenalidomide for Follicular Lymphoma

This study is testing a new combination of medicines for people with follicular lymphoma that has come back or not responded to previous treatments. The study will look at valemetostat, given by mouth, in combination with rituximab (given through a vein) and lenalidomide (given by mouth). Researchers want to find the safest and most effective dose of this combination. They will also check how well the drugs work and any side effects. You may be able to join if you are 18 or older, have follicular lymphoma grades 1-3A, and have already received at least one other treatment for your lymphoma. The study is currently recruiting a small number of participants, about 16 people.

Study design
This is an open-label study, meaning you and your doctors will know which treatments you are receiving. It is designed to enroll about 16 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track side effects through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05683171

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~16 participants
Updated 2026-06-29 on ClinicalTrials.gov
What's tested:RituximabLenalidomideValemetostat

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over through study completion; an average of 1 year.

Conditions

Lymphoma

Explore related trials

Follicular Lymphoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Chijioke Nze, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

In phase 1, creatinine clearance must be \>60 mL/minute
In Phase 2, creatinine clearance must be ≥30 mL/minute. 8. Adequate bone marrow function:

What this trial measures

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0through study completion; an average of 1 year.